These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

128 related articles for article (PubMed ID: 7014931)

  • 1. Treatment of residual, non-infiltrating bladder cancer with bacillus Calmette-Guerin.
    Morales A; Ottenhof P; Emerson L
    J Urol; 1981 May; 125(5):649-51. PubMed ID: 7014931
    [No Abstract]   [Full Text] [Related]  

  • 2. Antiproliferative effect of IL-6 on transitional cell carcinoma of the bladder. Insight into mechanisms of bacillus Calmette-Guerin immunotherapy.
    Alexandroff AB; Black J; Esuvaranathan K; James K
    Biochem Soc Trans; 1997 May; 25(2):270S. PubMed ID: 9191314
    [No Abstract]   [Full Text] [Related]  

  • 3. Nephrogenic adenoma in a patient with transitional cell carcinoma of the bladder receiving intravesical bacillus Calmette-Guérin.
    Oyama N; Tanase K; Akino H; Mori H; Kanamaru H; Okada K
    Int J Urol; 1998 Mar; 5(2):185-7. PubMed ID: 9559850
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Bacillus Calmette-Guérin strain differences as the basis for immunotherapies against bladder cancer.
    Miyazaki J; Onozawa M; Takaoka E; Yano I
    Int J Urol; 2018 May; 25(5):405-413. PubMed ID: 29506322
    [TBL] [Abstract][Full Text] [Related]  

  • 5. High-grade transitional cell carcinoma of the bladder in a 5-year-old boy successfully treated with partial cystectomy and intravesical bacillus Calmette-Guerin.
    Khandelwal P; Brewer AJ; Minevich E; Miles L; Geller JI
    J Pediatr Hematol Oncol; 2014 May; 36(4):e234-6. PubMed ID: 23619109
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Long term protection in bladder cancer following intralesional immunotherapy.
    Reichert DF; Lamm DL
    J Urol; 1984 Sep; 132(3):570-3. PubMed ID: 6381762
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Intravesical bacillus Calmette-Guerin therapy for superficial bladder cancer: effect of bacillus Calmette-Guerin viability on treatment results.
    Kelley DR; Ratliff TL; Catalona WJ; Shapiro A; Lage JM; Bauer WC; Haaff EO; Dresner SM
    J Urol; 1985 Jul; 134(1):48-53. PubMed ID: 3892051
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Nephrogenic adenoma associated with intravesical bacillus Calmette-Guerin treatment: a report of 2 cases.
    Stilmant MM; Siroky MB
    J Urol; 1986 Feb; 135(2):359-61. PubMed ID: 3511292
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Bacillus Calmette-Guerin for superficial transitional cell carcinoma of the bladder.
    Schellhammer PF; Ladaga LE; Fillion MB
    J Urol; 1986 Feb; 135(2):261-4. PubMed ID: 3511283
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Tubercular prostatic abscess as a complication of intravesical bacillus Calmette-Guérin immunotherapy.
    Aust TR; Massey JA
    Int J Urol; 2005 Oct; 12(10):920-1. PubMed ID: 16323989
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Bacillus Calmette-Guerin versus doxorubicin versus thiotepa: a randomized prospective study in 202 patients with superficial bladder cancer.
    Martínez-Piñeiro JA; Jiménez León J; Martínez-Piñeiro L; Fiter L; Mosteiro JA; Navarro J; García Matres MJ; Cárcamo P
    J Urol; 1990 Mar; 143(3):502-6. PubMed ID: 2106041
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A report of iliac muscle abscess due to Mycobacterium bovis after bacillus Calmette-Guerin therapy for bladder cancer.
    Talluri SK; Marigowda L; Besur S; Talluri J; Forstall GJ
    South Med J; 2010 Apr; 103(4):369-70. PubMed ID: 20224496
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Intraluminal interleukin 2 and bacillus Calmette-Guerin for treatment of bladder cancer: a preliminary report.
    Merguerian PA; Donahue L; Cockett AT
    J Urol; 1987 Feb; 137(2):216-9. PubMed ID: 3492613
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The expression level of ligands for natural killer cell receptors predicts response to bacillus Calmette-Guerin therapy: a pilot study.
    Yutkin V; Pode D; Pikarsky E; Mandelboim O
    J Urol; 2007 Dec; 178(6):2660-4. PubMed ID: 17945285
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Intracavitary Bacillus Calmette-Guerin in the treatment of superficial bladder tumors.
    Morales A; Eidinger D; Bruce AW
    J Urol; 1976 Aug; 116(2):180-3. PubMed ID: 820877
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Recurrence and progression of T1G3 transitional cell carcinoma of the bladder treated with intravesical bacillus Calmette-Guérin.
    Günlüsoy B; Değirmenci T; Arslan M; Nergiz N; Minareci S; Ayder AR
    Urol Int; 2005; 75(2):107-13. PubMed ID: 16123562
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A randomized prospective comparison of oral versus intravesical and percutaneous bacillus Calmette-Guerin for superficial bladder cancer.
    Lamm DL; DeHaven JI; Shriver J; Crispen R; Grau D; Sarosdy MF
    J Urol; 1990 Jul; 144(1):65-7. PubMed ID: 2193172
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Importance of urinary interleukin-18 in intravesical immunotherapy with bacillus calmette-guérin for superficial bladder tumors.
    Eto M; Koga H; Noma H; Yamaguchi A; Yoshikai Y; Naito S
    Urol Int; 2005; 75(2):114-8. PubMed ID: 16123563
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pleural effusion after intravesical administration of bacillus Calmette-Guérin.
    Roca Noval A; Cisneros C; García-Pérez FJ; Domingo D
    Arch Bronconeumol; 2017 Dec; 53(12):694-695. PubMed ID: 28476221
    [No Abstract]   [Full Text] [Related]  

  • 20. Sequential immunocytological evaluation of murine transitional cell carcinoma during intralesional bacillus Calmette-Guerin and interleukin-2 immunotherapy.
    Sosnowski JT; De Haven JI; Abraham FM; Riggs DR; Lamm DL
    J Urol; 1992 May; 147(5):1439-43. PubMed ID: 1569700
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.